Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LFVN with free AI briefings, catalyst countdowns, and dilution alerts.

LFVN · Lifevantage Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13.7M Cash on Hand
CF+ Cash Runway
Follow LFVN by email Get an email when LFVN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LFVN, unsubscribe in one click. Privacy

📣 What LFVN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

LFVN holds $13.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LFVN files for a raise →

👥 Who Owns LFVN

Insiders 24.2% Institutions (112 holders) 55.5% Public and other holders 20.3%
HolderTypeShares% of sharesAs of
The Capital Management Corporation Institution (13G, 5%+) 2,307,489 18.19% 2026-09-30
Judd Dayton
Director
Insider 847,572 6.68% 2026-11-05
Steven R Fife
President and CEO, Director
Insider 735,471 5.80% 2026-04-01
Renaissance Technologies LLC Institution (13G, 5%+) 669,418 5.28% 2026-04-01
Terrence Moorehead
President and CEO, Director · +289,855 options
Insider 501,879 3.96% 2026-10-07
Carl Aure
Chief Financial Officer · +53,623 options
Insider 191,784 1.51% 2026-10-07
Darwin Lewis
Director
Insider 156,132 1.23% 2026-11-05
Kristen Cunningham
Chief Sales Officer · +49,275 options
Insider 152,375 1.20% 2026-10-07
Raymond B Greer
Director
Insider 130,707 1.03% 2026-11-05
Alissa Neufeld
General Counsel
Insider 112,744 0.89% 2026-07-01
Michael A Beindorff
Director
Insider 82,709 0.65% 2026-11-12
Cynthia Latham
Director
Insider 64,879 0.51% 2025-11-06

Share count 12,682,221 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LFVN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LFVN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.